Menopausal hormone therapy: route of administration and platelet-derived microparticles

Menopausal hormone therapy: route of administration and platelet-derived microparticles - Menopausal hormone therapy: route of administration and platelet-derived microparticles

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013273

Enrollment

Registered

2014-02-25

Start date

2014-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopausal symptoms

Interventions

4-week treatment with oral estradiol 1 mg/day 4-week treatment with transdermal estradiol 50 mcg/day

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: women who are bothered by menopausal symptoms

Exclusion criteria

Exclusion criteria: severe liver dysfunction, present and past history of breast or endometrial cancer, abnormal uterine bleeding with unknown etiology, pregnancy, present and past history of venous thromboembolism, coronary heart diseases, or stroke

Design outcomes

Primary

Measure	Time frame
PDMP concentration	—

Countries

Japan

Contacts

Public ContactMasakazu Terauchi

Tokyo Medical and Dental University Department of Women's Health

teragyne@tmd.ac.jp03-5803-4605

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026